Response to McNaughton and colleagues regarding their article--interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?
Rawson
Nola
N
D003362:Cost-Benefit Analysis; D006233:Persons with Disabilities / Q000534:rehabilitation; D006801:Humans; D016899:Interferon-beta / Q000191:economics* / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009313:National Health Programs / Q000191:economics*; D009520:New Zealand; D011057:Politics
D016899:Interferon-beta